Neumora Therapeutics, Inc. (NMRA)
1.51
+0.01
(+0.67%)
USD |
NASDAQ |
Aug 26, 10:43
Neumora Therapeutics Enterprise Value : 216.69M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 216.69M |
| August 24, 2026 | 221.37M |
| August 21, 2026 | 240.99M |
| August 20, 2026 | 219.50M |
| August 19, 2026 | 242.85M |
| August 18, 2026 | 242.85M |
| August 17, 2026 | 220.43M |
| August 14, 2026 | 235.38M |
| August 13, 2026 | 259.67M |
| August 12, 2026 | 255.93M |
| August 11, 2026 | 254.06M |
| August 10, 2026 | 239.12M |
| August 07, 2026 | 240.99M |
| August 06, 2026 | 242.85M |
| August 05, 2026 | 237.25M |
| August 04, 2026 | 235.38M |
| August 03, 2026 | 242.85M |
| July 31, 2026 | 237.25M |
| July 30, 2026 | 244.72M |
| July 29, 2026 | 244.72M |
| July 28, 2026 | 250.33M |
| July 27, 2026 | 246.59M |
| July 24, 2026 | 214.83M |
| July 23, 2026 | 227.91M |
| July 22, 2026 | 224.17M |
| Date | Value |
|---|---|
| July 21, 2026 | 238.18M |
| July 20, 2026 | 240.99M |
| July 17, 2026 | 237.25M |
| July 16, 2026 | 235.38M |
| July 15, 2026 | 240.99M |
| July 14, 2026 | 231.64M |
| July 13, 2026 | 235.38M |
| July 10, 2026 | 250.33M |
| July 09, 2026 | 244.72M |
| July 08, 2026 | 233.51M |
| July 07, 2026 | 259.67M |
| July 06, 2026 | 252.20M |
| July 02, 2026 | 248.46M |
| July 01, 2026 | 239.12M |
| June 30, 2026 | 254.06M |
| June 29, 2026 | 219.61M |
| June 26, 2026 | 205.04M |
| June 25, 2026 | 181.36M |
| June 24, 2026 | 172.25M |
| June 23, 2026 | 199.57M |
| June 22, 2026 | 185.00M |
| June 18, 2026 | 181.36M |
| June 17, 2026 | 185.00M |
| June 16, 2026 | 190.47M |
| June 15, 2026 | 72.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 686.06B |
| Indivior Pharmaceuticals, Inc. | 4.531B |
| Liquidia Corp. | 6.179B |
| BioAge Labs, Inc. | 146.89M |
| LB Pharmaceuticals, Inc. | 1.077B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.08M |
| Total Expenses (Quarterly) | 43.08M |
| EPS Diluted (Quarterly) | -0.2327 |
| Earnings Yield | -81.68% |
| Normalized Earnings Yield | -80.25 |